An Open Label, 1-Sequence Cross-Over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL) With Quetiapine Fumarate Extended Release (SEROQUEL XR) in Healthy Male Volunteers.

Trial Profile

An Open Label, 1-Sequence Cross-Over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL) With Quetiapine Fumarate Extended Release (SEROQUEL XR) in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders; Depressive disorders; Generalised anxiety disorder; Personality disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top